Aaron W Michels

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. pmc Targeting the trimolecular complex
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, 1775 Aurora Court, MS A140, Aurora, CO 80045, USA Electronic address
    Clin Immunol 149:339-44. 2013
  2. pmc Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045, USA
    Diabetes Technol Ther 15:S2-8-S2-12. 2013
  3. pmc Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO 80045, USA
    J Immunol 187:5921-30. 2011
  4. doi request reprint Autoimmune polyendocrine syndrome type 1 (APS-1) as a model for understanding autoimmune polyendocrine syndrome type 2 (APS-2)
    A W Michels
    Department of Medicine, Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Aurora, Colorado 80045, United States
    J Intern Med 265:530-40. 2009
  5. pmc 2011 Update: antigen-specific therapy in type 1 diabetes
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045, USA
    Curr Opin Endocrinol Diabetes Obes 18:235-40. 2011
  6. pmc The anti-insulin trimolecular complex in type 1 diabetes
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045, USA
    Curr Opin Endocrinol Diabetes Obes 17:329-34. 2010
  7. pmc Immunologic endocrine disorders
    Aaron W Michels
    Department of Medicine, Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO 80045, USA
    J Allergy Clin Immunol 125:S226-37. 2010
  8. pmc γδ T cells recognize the insulin B:9-23 peptide antigen when it is dimerized through thiol oxidation
    M Kemal Aydintug
    Integrated Department of Immunology, National Jewish Health and University of Colorado Denver, 1400 Jackson Street, Denver, CO 80206, USA
    Mol Immunol 60:116-28. 2014
  9. pmc Immune intervention in type 1 diabetes
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO 80045, USA
    Semin Immunol 23:214-9. 2011
  10. ncbi request reprint α1-Antitrypsin Therapy Downregulates Toll-Like Receptor-Induced IL-1β Responses in Monocytes and Myeloid Dendritic Cells and May Improve Islet Function in Recently Diagnosed Patients With Type 1 Diabetes
    Peter A Gottlieb
    Barbara Davis Center for Childhood Diabetes P A G, A K A, A W M, D Z and Division of Infectious Diseases C A D, University of Colorado Denver, Aurora, Colorado 80045 Department of Clinical Biochemistry and Pharmacology E C L, Faculty of Health Sciences, Ben Gurion University of the Negev, 84105 Beer Sheva, Israel and Department of Medicine L S, Division of Infectious Diseases, Veterans Affairs Medical Center and University of Colorado Denver, Denver, Colorado 80202
    J Clin Endocrinol Metab 99:E1418-26. 2014

Collaborators

Detail Information

Publications12

  1. pmc Targeting the trimolecular complex
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, 1775 Aurora Court, MS A140, Aurora, CO 80045, USA Electronic address
    Clin Immunol 149:339-44. 2013
    ..This review focuses on the components of the anti-insulin trimolecular complex, registers of insulin peptide binding to 'diabetogenic' MHC class II molecules, and therapies targeting each component of the trimolecular complex. ..
  2. pmc Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045, USA
    Diabetes Technol Ther 15:S2-8-S2-12. 2013
    ..It is our belief that targeting this complex with safe and specific therapies will lead to the prevention of type 1 diabetes and an improved understanding as to why diabetes develops...
  3. pmc Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO 80045, USA
    J Immunol 187:5921-30. 2011
    ..These studies present a novel method for identifying small molecules capable of both stimulating and inhibiting T cell responses, with potentially therapeutic applications...
  4. doi request reprint Autoimmune polyendocrine syndrome type 1 (APS-1) as a model for understanding autoimmune polyendocrine syndrome type 2 (APS-2)
    A W Michels
    Department of Medicine, Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Aurora, Colorado 80045, United States
    J Intern Med 265:530-40. 2009
    ..With continued basic and clinical research, therapies aimed at treating the underlying autoimmunity and disease prevention should become possible...
  5. pmc 2011 Update: antigen-specific therapy in type 1 diabetes
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045, USA
    Curr Opin Endocrinol Diabetes Obes 18:235-40. 2011
    ..To update on the clinical trials using antigen-specific therapies in autoimmune diabetes...
  6. pmc The anti-insulin trimolecular complex in type 1 diabetes
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045, USA
    Curr Opin Endocrinol Diabetes Obes 17:329-34. 2010
    ..Description of the immunologic components needed for autoimmune diabetes...
  7. pmc Immunologic endocrine disorders
    Aaron W Michels
    Department of Medicine, Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO 80045, USA
    J Allergy Clin Immunol 125:S226-37. 2010
    ..As a result, there are now iatrogenic autoimmune disorders arising from the treatment of chronic viral infections and malignancies...
  8. pmc γδ T cells recognize the insulin B:9-23 peptide antigen when it is dimerized through thiol oxidation
    M Kemal Aydintug
    Integrated Department of Immunology, National Jewish Health and University of Colorado Denver, 1400 Jackson Street, Denver, CO 80206, USA
    Mol Immunol 60:116-28. 2014
    ..This observation is consistent with the notion that γδ T cell recognition depends on the secondary structure of the dimerized insulin B:9-23 antigen. ..
  9. pmc Immune intervention in type 1 diabetes
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO 80045, USA
    Semin Immunol 23:214-9. 2011
    ..This review focuses on immune intervention for the prevention and amelioration of human T1D with a focus on potential immune suppressive, antigen specific and environmental therapies...
  10. ncbi request reprint α1-Antitrypsin Therapy Downregulates Toll-Like Receptor-Induced IL-1β Responses in Monocytes and Myeloid Dendritic Cells and May Improve Islet Function in Recently Diagnosed Patients With Type 1 Diabetes
    Peter A Gottlieb
    Barbara Davis Center for Childhood Diabetes P A G, A K A, A W M, D Z and Division of Infectious Diseases C A D, University of Colorado Denver, Aurora, Colorado 80045 Department of Clinical Biochemistry and Pharmacology E C L, Faculty of Health Sciences, Ben Gurion University of the Negev, 84105 Beer Sheva, Israel and Department of Medicine L S, Division of Infectious Diseases, Veterans Affairs Medical Center and University of Colorado Denver, Denver, Colorado 80202
    J Clin Endocrinol Metab 99:E1418-26. 2014
    ..Recent studies have implicated proinflammatory responses in the mechanism of type 1 diabetes (T1D)...
  11. doi request reprint Autoimmune polyglandular syndromes
    Aaron W Michels
    Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, 1775 Aurora Court, MS B140, PO Box 6511, Aurora, CO 80045, USA
    Nat Rev Endocrinol 6:270-7. 2010
    ..This Review discusses the genetic basis of APS-1, APS-2 and IPEX syndrome, with an emphasis on the mechanisms of autoimmunity and presents currently available therapies to treat their underlying autoimmune disorders...